Back to Journals » OncoTargets and Therapy » Volume 7

Outcomes analysis of an alternative formulation of PEGylated liposomal doxorubicin in recurrent epithelial ovarian carcinoma during the drug shortage era

Authors Berger J, Smith A, Zorn K, Sukumvanich P, Olawaiye A, Kelley J, Krivak T

Received 22 February 2014

Accepted for publication 7 April 2014

Published 8 August 2014 Volume 2014:7 Pages 1409—1413


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Jessica L Berger, Ashlee Smith, Kristin K Zorn, Paniti Sukumvanich, Alexander B Olawaiye, Joseph Kelley, Thomas C Krivak

Magee-Womens Hospital, University of Pittsburgh Medical Center, Division of Gynecologic Oncology, Pittsburgh, PA, USA

Corrigendum for this paper has been published

A Letter to the Editor has been received and published for this article


Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]